Perspective Therapeutics has appointed Joel Sendek as Chief Financial Officer, effective immediately, as the radiopharmaceutical company advances its clinical pipeline of targeted alpha therapy programs. The appointment brings significant biotech finance expertise to support the company's development of 212Pb-based cancer treatments currently in Phase 1/2a trials.
Sendek brings extensive leadership experience, having previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. His track record includes raising over $2.5 billion in biotech financing and completing multiple transactions across his CFO tenure. Prior to his executive roles, Sendek held senior equity research positions at Stifel as Head of Healthcare Equity Research, and at Lazard and Oppenheimer as Head of Healthcare Life Sciences Research. The Wall Street Journal recognized him as an All-Star Analyst with a #1 ranking in stock picking.
Strategic Leadership for Clinical Advancement
"Joel's financial leadership and expertise in biotech will be extremely valuable as we advance our clinical programs and work to establish the Company as a leader in the targeted alpha radiopharmaceutical field," said CEO Thijs Spoor. "His appointment comes at an exciting time for Perspective, with ongoing progress across all three of our clinical programs."
Sendek expressed confidence in the company's therapeutic approach, stating, "Perspective's technology has the potential to significantly expand the breadth of tumors that can be treated with radiopharmaceutical therapy. I'm joining because I view Perspective as the most attractive company within one of the most dynamic subsectors of the biotech industry today."
Proprietary Alpha-Emitting Technology Platform
Perspective Therapeutics has developed proprietary technology utilizing the alpha-emitting isotope 212Pb to deliver targeted radiation specifically to cancer cells via specialized targeting moieties. The company's theranostic approach combines therapeutic and diagnostic capabilities, incorporating the same targeting moieties in complementary imaging diagnostics to personalize treatment and optimize patient outcomes.
This integrated platform enables physicians to visualize specific tumors and then treat them with the goal of improving efficacy while minimizing toxicity. The company is currently advancing three clinical programs in Phase 1/2a imaging and therapy trials in the United States: VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors.
Manufacturing Infrastructure Development
The company is expanding its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator technology. This infrastructure is designed to deliver patient-ready product candidates for both clinical trials and future commercial operations, supporting the company's goal of establishing leadership in the targeted alpha radiopharmaceutical field.
Sendek succeeds Juan Graham, who is departing the company. "I personally would like to thank Juan for his contributions and wish him well in his future endeavors," Spoor added. The new CFO's priority will be supporting the advancement of the innovative platform and ensuring adequate resources are in place to realize its full therapeutic potential.
